About BioVaxys

A Clinical-Stage
Immunotherapeutics Company

SARS-CoV-2 and Cancer Vaccine
Platforms in Development

BioVaxys is a clinical-stage biopharma developing antiviral & anticancer vaccine platforms. The Company is evaluating a potential SARS-CoV-2 vaccine based on its haptenized viral protein technology, and advancing a compassionate use trial in the EU to evaluate its haptenized cell vaccine for late-stage ovarian cancer.

  1. SARS-CoV-2 Vaccine

  2. Ovarian Cancer Vaccine

T-Cell Antigen Discovery Program

In addition to our haptenized cell vaccines for ovarian cancer and other tumor types, we are exploring ways we can leverage our technology platform in the field of Adoptive Immunotherapy, which is also of significant interest in the immune-oncology market.  Adoptive Immunotherapy is where T-cells are collected from a patient and grown in the laboratory. This increases the number of T-cells that are able to kill cancer cells.

Our ovarian cancer clinical studies and manufacturing protocol will provide us with the unique ability to collect T-cells from patients, both pre- and post- vaccine administration. BioVaxys’ objective is to use T-cells made responsive to it’s vaccines to identify new antigens that can be synthesized and explored, as they may prove useful as diagnostic agents or as new, chemically-defined, patient-specific vaccines. These novel antigens may be distinct for each patient, or present across all tumor cells.  BioVaxys intends to explore partnerships with CAR T/TCR cell therapy companies to identify novel cancer antigens eliciting a T-cell response, which will develop extensive new intellectual property for BioVaxys.

Our Intellectual Property

  • Exclusive license from Thomas Jefferson University for patents related to haptenized cancer vaccines
    Thomas Jefferson University

  • US and national patent applications in multiple countries based on internal discoveries for a bihaptenized cancer vaccine platform in combination with checkpoint inhibitors
  • US and International PCT applications based on internal discoveries related to a haptenized viral antigen vaccines platform.
  • US Patent Application for diagnostics to detect T cell-mediated immune response

Executive Team & Board
of Directors

James Passin

James Passin

Founder, Chief Executive Officer and Director

Mr. James Passin is a former hedge fund and private equity fund manager at FGS Advisors, LLC, an affiliate of New York-based  Firebird  Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies,  Inc., one of the world’s  first cellular immunotherapeutic vaccine  companies. He is a director of  several public companies, including TraceSafe Inc. (CSE: TSF) and BDSec JSC  (MSE: BDS), is a Chartered Market Technician and member of the CMT Association..

Kenneth Kovan

Kenneth Kovan

Founder, President and Chief Operating Officer

Mr. Kovan has over 30 years of experience in biopharmaceuticals commercial development. He recently served as Corporate Development Partner with Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012 that specializes in corporate development, technology licensing, and business planning. He is an experienced former biotech CEO and board member, and founder of biotechnology companies including the former Avax Technologies, Inc. Mr. Kovan’s professional background includes several years in technology transfer with Thomas Jefferson University, Strategic Marketing with GlaxoSmithKline, and Global New Product Development with Wyeth-Ayerst Pharmaceuticals. His therapeutic experience includes infectious disease, antivirals, oncology, vaccines, cell/gene therapy, and gene editing. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets, and has worked in Europe for several years.

David Berd, MD

Founder and Chief Medical Officer

Dr. David Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He cofounded cancer immunotherapy company AVAX Technologies, is the inventor of the cancer vaccines MVax™ and OVax™, and served as Chief Medical Officer 2005-2008. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. He has ten issued patents dealing with cancer vaccines. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.

Craig Loverock, CPA

Chief Financial Officer

Craig Loverock is a Chartered Professional Accountant with over 20 years’ experience in accounting and finance roles in Canada, the United States, and the United Kingdom. He brings with him public company reporting and transactional experience, as well as having provided CFO consulting services to a number of private high growth technology businesses, serving as the Senior Financial Advisor to the Chairman at Magna International, and acting as the Chief Compliance Officer and CFO for a private equity firm. Mr. Loverock received his B.Comm (Hons) from Carleton University in 1994 and received his Chartered Accountant’s designation from the Institute of Chartered Accountants, Ontario in 1997. He is currently the treasurer of the Durham Community Foundation.

David Wang


David Wang is a seasoned medical technology executive and Healthcare Consultant for South America with Omron, a US$1.5 billion market capitalization company listed on the Tokyo Stock Exchange.Previously, he was CEO of CAUS Capital and of Beijing Century Medical.Mr. Wang received his MBA from The University of International Business and Economics in Beijing.He is fluent in Chinese and Japanese.

Anthony Dutton


Anthony brings more than two decades of senior corporate leadership with expertise in strategic planning, financing, and M&A with broad industry experience, including manufacturing, cannabis, and oil and gas. He is a partner at HighMont Advisors and most recently was co-founder and CEO of Cannex Capital Group Inc. (“Cannex”) a pioneering US cannabis company, before its 2019 acquisition of 4Front Holdings Ltd. to create 4Front Ventures (CSE:FFNT), a leading multi-state cannabis operator. Prior to Cannex, Anthony was CEO, President and a director of IBC Advanced Alloys Corp. (“IBC”)(TSX-V:IB) a high performance alloys company serving the defense, aerospace, automotive, and precision manufacturing sectors. He currently serves on the board of Sanatana Resources Inc. (TSX.V:STA) and has a B.A. (Econ.) from the University of British Columbia, an M.Arch. from Dalhousie University and an MBA from the Cranfield School of Management in the UK.


Charles J. Dunton, MD


Dr. Dunton, a top global opinion leader, is a gynecologist/oncologist in Indiana. He received his medical degree from Jefferson Medical College and has been in practice for more than 30 years.  Dr. Dunton has been Chief, Division of Gynecologic Oncology Department of Obstetrics and Gynecology, Main Line Health and Professor, Department of Obstetrics and Gynecology, Jefferson Medical College, and has been named one of America’s Top Doctors for Cancer by U.S. News & World Report.  His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus (“HPV”).  He is Past President and board member of the American Society for Colposcopy and Cervical Pathology and was on the Editorial Board of the Journal of Lower Genital Tract Disease.  Dr Dunton is familiar with BVX-0918A, having been involved in the early clinical trials of the first generation of the vaccine at Thomas Jefferson University. Most recently, he was Global Medical Director, Aspira Women’s Health (NASDAQ:AWH).

Yvelise Barrios, MD


Dr. Barrios is a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, with a clinical focus on histocompatibility, autoimmune diseases and allergy, and is senior Immunology consultant for primary immunodeficiency diseases.  Her lab is the Reference Laboratory for kidney transplantation of the Canary Islands Province in Spain.  Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital. She received her PhD on Active Immunotherapy in B-cell Tumors, from Universidad Autonoma, Madrid, and did her post-doctoral in phage display expression of antibody fragments in Immunotechnology at Lund University in Sweden. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity (“DTH”), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Kartik Chandran, PhD


Dr. Chandran is Professor of Microbiology & Immunology and the Harold and Muriel Block Scholar in Virology at Albert Einstein College of Medicine in New York City, where he oversees a team of researchers engaged in basic and translational research on emerging RNA viruses and investigating the molecular mechanisms of viral infection, with a focus on coronaviruses and filoviruses, including SARS-CoV-2, Ebola virus and Marburg virus. Dr. Chandran received his Ph.D. in Biochemistry at the University of Wisconsin-Madison, followed by research fellowships  at Harvard University and Brigham and Womens Hospital prior to joining Einstein.  

Adam Coutts, PhD


Dr. Coutts is a Senior Research Fellow at Magdalene CollegeUniversity of Cambridge and a Research Associate in the Department of Sociology, University of Cambridge.  Dr. Coutts’ research focuses on the social and political determinants of health looking at how non-health sector public policies affect the health and wellbeing of vulnerable groups and how government interventions can be used to help them. Dr. Coutts holds a PhD from the Department of SociologyUniversity of Cambridge and has held post-doctoral fellowships at Cambridge, and the Department of Politics and International Relations, University of Oxford, Nuffield College.  Dr. Coutts is also a research associate at the Centre for Business Research, Cambridge.

Shmuel Farhi


Mr. Farhi is founder and President of Farhi Holding Corporation, a Canadian company that owns more than four million square feet of properties across Ontario.  He is a prolific investor in the Canadian, American, and Israeli biotech industry.